Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

In vitro activity of econazole in comparison with three common antifungal agents against clinical Candida strains isolated from superficial infections.

Abastabar M, Shokohi T, Rouhi Kord R, Badali H, Hashemi SJ, Ghasemi Z, Ghojoghi A, Baghi N, Abdollahi M, Hosseinpoor S, Rahimi N, Seifi Z, Gholami S, Haghani I, Jabari MR, Pagheh A.

Curr Med Mycol. 2015 Dec;1(4):7-12. doi: 10.18869/acadpub.cmm.1.4.7.

2.

Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.

Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD.

Front Microbiol. 2017 Jan 12;7:2173. doi: 10.3389/fmicb.2016.02173. eCollection 2016. Review.

3.

A Prospective Surveillance Study of Candidaemia: Epidemiology, Risk Factors, Antifungal Treatment and Outcome in Hospitalized Patients.

Rajendran R, Sherry L, Deshpande A, Johnson EM, Hanson MF, Williams C, Munro CA, Jones BL, Ramage G.

Front Microbiol. 2016 Jun 16;7:915. doi: 10.3389/fmicb.2016.00915. eCollection 2016.

4.

Screening of Pharmacologically Active Small Molecule Compounds Identifies Antifungal Agents Against Candida Biofilms.

Watamoto T, Egusa H, Sawase T, Yatani H.

Front Microbiol. 2015 Dec 22;6:1453. doi: 10.3389/fmicb.2015.01453. eCollection 2015.

5.

The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study.

Wang H, Liu N, Yin M, Han H, Yue J, Zhang F, Shan T, Guo H, Wu D.

BMC Infect Dis. 2014 Nov 25;14:609. doi: 10.1186/s12879-014-0609-x.

6.

The Candida pathogenic species complex.

Turner SA, Butler G.

Cold Spring Harb Perspect Med. 2014 Sep 2;4(9):a019778. doi: 10.1101/cshperspect.a019778. Review.

7.

Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to Echinocandins in Candida glabrata.

Pham CD, Bolden CB, Kuykendall RJ, Lockhart SR.

J Clin Microbiol. 2014 Mar;52(3):790-5. doi: 10.1128/JCM.03378-13. Epub 2013 Dec 18.

8.

Antifungal application of nonantifungal drugs.

Stylianou M, Kulesskiy E, Lopes JP, Granlund M, Wennerberg K, Urban CF.

Antimicrob Agents Chemother. 2014;58(2):1055-62. doi: 10.1128/AAC.01087-13. Epub 2013 Nov 25.

9.

Synthesis and Biological Evaluation of Novel Alkyl-Imidazolyl Carbinols and their Esters: Potent Antimycotics.

Krauss J, Gratzl C, Sturm V, Müller C, Staudacher V, Schmidt CQ, Bracher F.

Sci Pharm. 2013 Sep 2;81(3):641-50. doi: 10.3797/scipharm.1304-17. Print 2013 Jul-Sep.

10.

Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility.

Han JH, Bilker WB, Nachamkin I, Tolomeo P, Mao X, Fishman NO, Lautenbach E.

Infect Control Hosp Epidemiol. 2013 Oct;34(10):1070-6. doi: 10.1086/673155. Epub 2013 Aug 23.

11.

Temporal changes in resistance mechanisms in colonizing Escherichia coli isolates with reduced susceptibility to fluoroquinolones.

Han JH, Nachamkin I, Tolomeo P, Mao X, Bilker WB, Lautenbach E.

Diagn Microbiol Infect Dis. 2013 Aug;76(4):491-6. doi: 10.1016/j.diagmicrobio.2013.04.018. Epub 2013 May 27.

12.

Risk factors for efflux pump overexpression in fluoroquinolone-resistant Escherichia coli.

Han JH, Nachamkin I, Tolomeo P, Mao X, Bilker WB, Lautenbach E.

J Infect Dis. 2012 Nov 15;206(10):1597-603. doi: 10.1093/infdis/jis567. Epub 2012 Sep 10.

13.

The effect of staphylococcal cassette chromosome mec (SCCmec) type on clinical outcomes in methicillin-resistant Staphylococcus aureus bacteremia.

Han JH, Edelstein PH, Bilker WB, Lautenbach E.

J Infect. 2013 Jan;66(1):41-7. doi: 10.1016/j.jinf.2012.09.001. Epub 2012 Sep 6.

14.

Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia.

Han JH, Mascitti KB, Edelstein PH, Bilker WB, Lautenbach E.

Antimicrob Agents Chemother. 2012 Oct;56(10):5164-70. doi: 10.1128/AAC.00757-12. Epub 2012 Jul 23.

15.

Derivation and validation of clinical prediction rules for reduced vancomycin susceptibility in Staphylococcus aureus bacteraemia.

Han JH, Bilker WB, Edelstein PH, Mascitti KB, Lautenbach E.

Epidemiol Infect. 2013 Jan;141(1):165-73. doi: 10.1017/S0950268812000295. Epub 2012 Apr 10.

16.

Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.

Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, Wiener-Well Y, Weinberger M, Zimhony O, Chowers M, Weber G, Potasman I, Chazan B, Kassis I, Shalit I, Block C, Keller N, Kontoyiannis DP, Giladi M; Israeli Candidemia Study Group.

Antimicrob Agents Chemother. 2012 May;56(5):2518-23. doi: 10.1128/AAC.05947-11. Epub 2012 Feb 6.

17.

Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.

Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F; French Mycosis Study Group.

Antimicrob Agents Chemother. 2011 Feb;55(2):532-8. doi: 10.1128/AAC.01128-10. Epub 2010 Nov 15.

18.

The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.

Kourkoumpetis TK, Velmahos GC, Ziakas PD, Tampakakis E, Manolakaki D, Coleman JJ, Mylonakis E.

Mycopathologia. 2011 Feb;171(2):85-91. doi: 10.1007/s11046-010-9369-3. Epub 2010 Oct 8.

19.

Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections.

Lee I, Morales KH, Zaoutis TE, Fishman NO, Nachamkin I, Lautenbach E.

Am J Infect Control. 2010 Nov;38(9):740-5. doi: 10.1016/j.ajic.2010.02.016. Epub 2010 Jun 12.

20.

Risk factors for fluconazole-resistant candidemia.

Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, Aznar-Martín J, Cisneros JM, Ortiz-Leyba C.

Antimicrob Agents Chemother. 2010 Aug;54(8):3149-54. doi: 10.1128/AAC.00479-10. Epub 2010 May 24.

Supplemental Content

Support Center